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Poloxamer 188 (P188), a water-soluble, synthetic copolymer with hydrophilic as well as lipophilic properties, is 
widely used as a cell protectant for bubble-induced shear during cultivation of suspension-adapted mammalian 
cells for large-scale production of protein-based therapeutics.  Poor cell growth and lower product yield has 
been recently observed at commercial scales in more than one Chinese hamster ovary-based manufacturing 
process within Roche network when specific lots of P188 were used.  An investigation is being conducted to 
unearth the root cause of “poor-performing” P188 lots and to identify means to mitigate the product supply risks.  
P188 raw material is currently sourced from a single vendor with additional supply constraints and risks 
associated with the impending change in the vendor manufacturing facility and location.  These factors further 
exacerbate the supply risks for the drugs produced by Roche.  A multi-pronged approach has been undertaken.  
A small-scale bioreactor based screening assay was developed where a model commercial cell line was 
subjected to a relatively high shear stress environment to differentiate between good-performing and poor-
performing lots.  To discern the root cause for the lot-specific loss of P188 functionality, analytical fingerprinting 
methods have been used to test different hypotheses including presence of high molecular weight species1. 
Pilot-scale fractionation was performed using good- and poor-performing P188 lots to isolate fractions with 
different molecular weight and characterized using methods including LC-MS/MS and 2D NMR. The structure 
elucidation results were further evaluated to discern the cell-protective functionality of the different fractions.  
Lastly, in order to ensure uninterrupted supply of our medicines to patients, a comprehensive evaluation of an 
alternate manufacturer of poloxamer 188 was performed.  Taken together, the findings from this investigation 
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